

Disclosure of Conflict of Interests

The California Society of Addiction Medicine adheres to the ACCME Standards for Integrity and Independence regarding industry support of continuing medical education. All faculty participating in continuing medical education activities sponsored by the California Society of Addiction Medicine are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in a continuing medical education presentation(s).

Unless otherwise noted, the faculty, planners, and staff have nothing to disclose.

Name	Reported Financial Relationship
Anthony Albanese, MD, FACP, DFASAM	"Speaker's Bureau: AbbVie Pharmaceuticals, Gilead Sciences (ended both in 2021) Consultant: AbbVie Pharmaceuticals, Gilead Sciences – (ended both in 2021)
Jeffrey DeVido, MD, MTS, FASAM, FAPA	Stock: Philip Morris/Altria; Merck
Tipu Khan, MD, FAAFP, FASAM	Speaker's Bureau - Abbvie Advisory Board Member – Alkermes
Marc Potenza, MD, PhD	Consulting Fee: Idorsia; AXA; Baria-Tek Advisory Board: Opiant Patent Application: Novartis (with Yale)
Lara Ray, PhD	Consultant: Alermes

All relevant financial relationships have been mitigated.

Discussion of Unlabeled Use

Faculty must disclose to participants, preferably in writing through course materials, that a product is off-label for use and/or will be discussing unlabeled/unapproved drugs or devices.